Skip to main content
. 2012 Feb 21;7(2):e32189. doi: 10.1371/journal.pone.0032189

Figure 1. Clinical outcomes of the patients included and clinical factors related to OS or hepatitis B relapse free survival.

Figure 1

(A) Clinical outcomes of 150 patients receiving LT. Hepatitis B (HepB) relapse did not occur in 8 patients who developed YMDD mutants and were switched to adefovir therapy before LT (left branch), whereas HepB relapse occurred in the remaining 142 patients who did not develop YMDD mutants. The clinical consequences of these patients were illustrated. The 33 patients with hepatitis B relapse were marked by a shaded background. (B) Comparison of OS between patients with (dashed line) and without (solid line) hepatitis B relapses. (C) Comparison of hepatitis B relapse free survival between patients receiving longer (>3 months; solid line) and shorter (≤3 months; dashed line) durations of pre-LT LAM treatment.